<DOC>
	<DOCNO>NCT00105235</DOCNO>
	<brief_summary>Alemtuzumab man-made antibody use treat certain blood disorder . Tacrolimus drug use decrease immune system activity people receive organ transplant new organ reject . This study determine whether treatment alemtuzumab tacrolimus effective preventing organ rejection maintain recipient 's health liver transplantation patient end-stage liver disease , whether gradual taper tacrolimus treatment safe patient .</brief_summary>
	<brief_title>Immune System Suppression With Alemtuzumab Tacrolimus Liver Transplantation Patients</brief_title>
	<detailed_description>Organ transplantation common procedure hospital , organ rejection serious side effect potential problem patient . Alemtuzumab monoclonal antibody bind deplete excess T cell bone marrow leukemia patient . In study , alemtuzumab destroy recipient 's white blood cell ( WBCs ) time transplantation . It hop WBCs produce alemtuzumab administration recognize transplant liver `` self '' reject new liver . Drugs suppress immune system , tacrolimus , contribute increased success transplantation . However , prevent organ rejection , transplant recipient need take immunosuppressive drug rest life , drug make patient susceptible infection , endanger health survival . Regimens less toxic eventually withdraw transplant recipient need . This study evaluate effect two in-patient dos alemtuzumab follow maintenance antirejection medication give liver transplant patient post-transplant . This study also determine post-transplant tacrolimus therapy slowly safely taper withdrawn year transplant . Participants study patient end-stage liver disease undergo liver transplantation start study . This study last least 2 year . Patients undergo liver transplantation start study Day 0 . Patients receive in-patient infusion alemtuzumab Days 0 4 . Starting Day 1 , patient receive oral cyclosporine , mycophenolate mofetil , and/or tacrolimus daily . Patients hospitalize least 1 week transplantation . Because suppression patient ' immune system alemtuzumab immunosuppressant , also receive prophylactic medication minimum 3 month transplantation prevent opportunistic infection . There least eight study visit ; occur Days 4 , 7 , 14 Months 1 , 3 , 6 , 9 , 12 . Patients liver biopsy Day 0 Months 6 12 . At Month 12 , participant assessment blood test determine meet certain criterion eligible undergo tacrolimus taper . Patients eligible taper undergo 12-month gradual withdrawal tacrolimus ; follow additional 2 year , study visit Months 18 , 24 , 30 , 36 . Patients ineligible tacrolimus tapering continue take antirejection medication duration study ; follow additional year , study visit Months 18 24 .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Diagnosis nonimmune , nonviral , endstage liver disease Need liver transplant Willing use acceptable mean contraception duration study Previous transplant Multiorgan transplant live donor transplant Donor liver donor positive antibody hepatitis B core antigen hepatitis C virus Donor liver nonheartbeating donor Liver failure due autoimmune disease , autoimmune hepatitis , primary sclerosing cholangitis , primary biliary cirrhosis Hepatitis B C virus infection HIV infection Stage III high hepatocellular cancer base pretransplant image History cancer . Patients hepatocellular cancer , adequately treat situ cervical carcinoma , adequately treat basal squamous cell carcinoma skin exclude . Active systemic infection time transplantation Clinically significant chronic renal , cardiovascular , cerebrovascular disease Any investigational drug within 6 week study entry Hypersensitivity alemtuzumab tacrolimus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>transplantation</keyword>
	<keyword>liver transplant</keyword>
	<keyword>rejection</keyword>
	<keyword>tolerance</keyword>
	<keyword>antibody induction</keyword>
</DOC>